An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Duloxetine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Registrational
- Sponsors Eli Lilly; Shionogi
- 20 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2013 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 21 Feb 2013 New trial record